Kelly Doering introduces the Peptide and Protein Bioanalysis Boot Camp

Kelly Doering introduces the Peptide and Protein Bioanalysis Boot Camp


Hi, my name is Kelly
Doering, and I’m a senior business manager
for a bioanalysis in DMPK with Waters Corporation. As most of us in this
field understand, a seismic shift is taking place
in drug development, where an increasingly greater
proportion of large molecule therapeutics is
coming to market. And the complexity
of these molecules is vast, ranging from peptides
to monoclonal antibodies, fusion proteins, and conjugated
modalities like ADCs. This is happening for
a variety of reasons. Biotherapeutic drug
to target interactions are often more optimal
than for small molecules. These therapeutics are
generally more profitable. They’re easier to patent and
more difficult to replicate as biosimilars, but quantifying
larger molecules in matrix is new to many of
us and presents a variety of challenges
that we don’t typically see with small molecules. On the whole,
peptides and proteins have a more diverse set
of chemical properties and tend to be
much more complex. And on top of that,
some dosing regimens demand high
analytical sensitivity in their measurement,
which poses its own set of challenges,
including interference from endogenous
peptides and proteins, more complex sample prep, and
potential loss of analyte, and a dilution of signal due
to multiple charge states and increased fragmentation. With that said, I’m
happy to introduce a new educational series, the
Peptide and Protein Bioanalysis boot camp, designed
to increase your lab’s proficiency in large
molecule quantification. Our team of bioanalysts knows
your challenges firsthand. They’ve taken their
collective experience and detailed workflows
for quantifying peptide and protein-based
biomarkers and biotherapeutics and broken them down into short
modules about 20 minutes each, covering the fundamentals of
peptide and protein structure through sample prep, LC
considerations, digestion of a large protein into peptides
for the surrogate peptide approach, or navigating
the choice between a tandem quad and a high-res
mass spec platform. Our goal is to
make you successful in this ever-changing
landscape of large molecule quantification. Take a look, share
with your colleagues, and let us know
how you’re doing. We’ve got your back.

Leave a Reply

Your email address will not be published. Required fields are marked *